英文名:CD19,B-CELLMARKER,90KD,CLONE:4G7/2E,MABANTI-HUMAN:FROZEN/NOPARAFFIN,IH 中文名: CBNumber:CB11222752 分子式: 分子量:0 MOL File:Mol file CD19,B-CELLMARKER,90KD,CLONE:4G7/2E,MABANTI-HUMAN:FROZEN/NOPARAFFIN,IH上下游产品信息 上游原料 下游产品 CD19,B-CELLMARKER,90KD,CLONE:4G7/2E...
However, CD19, another B cell marker, is more widely expressed and has emerged as a promising target in autoimmune diseases. CD19-targeted therapies, such as CAR T cells and Uplizna (inebilizumab), have demonstrated potential in treating refractory autoimmune diseases, including SSc....
因为该抗体Fc段通过去岩藻糖化的改造,因此其主要作用机制是通过抗体依赖性细胞毒作用(Antibody Dependent Cellular Cytotoxicity,ADCC)来杀伤B细胞,基于体内作用机制,本研究使用转基因细胞法通过检测抗CD19单抗的抗体依赖的细胞毒性(AntibodyDependent Cell mediated Cytotoxicity,...
作者惊奇地发现,有一小部分细胞,这些细胞同时表达CD19,和mural细胞的marker基因CD248 但这些细胞不表达B细胞的marker基因CD79A 这说明,在大脑里,是有表达CD19基因的细胞的。而且这些细胞不表达B细胞的marker基因CD79A 说明这些细胞既不是B细胞,也不是混合有B细胞的双细胞。 作者进一步观察到这些细胞还表达CD81基因,...
CD19 is a pan B cell marker that is recognized as an attractive target for antibody-based therapy of B-cell disorders including autoimmune disease and hematological malignancies. The object of this study was to stably express the human CD19 antigen in the murine NIH-3T3 cell line aimed to be...
CD19 MicroBeads were developed for positive selection or depletion of CD19+ B cells from different cell sources such as human PBMCs, bone marrow, lymphoid tissues, or cell cultures. Detailed product information Background information As a B cell lineage marker, the CD19 antigen is expressed from...
As a B cell lineage marker, CD19 is expressed from the early pro-B cell stage to the B cell lymphoblast stage; however, CD19 is down-regulated as B cells mature to plasma cells. The CD19 antigen is also expressed on most malignant B cells and on a subset of follicular dendritic cells...
CD19在B细胞反应调节因子中发挥正向调节作用,参与B细胞抗原受体(B cell receptor,BCR)识别抗原的过程,同时还在维持体液及抗原诱导的免疫反应和耐受诱导之间的平衡方面起着关键作 [2]用。CD19是成熟B细胞表面多分子复合物的重要成员,与补体受体CD21、CD81和CD225共同 [3]发挥作用 。该复合物通过调节内源性和受体...
Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains ...
接受CD19 CAR-T细胞疗法(CAR19)后发生进展的复发/难治性大B细胞淋巴瘤(LBCL)患者预后不佳。CD22表达于大多数B细胞淋巴瘤。本文报告了靶向CD22 (CAR22)的自体CAR-T细胞疗法用于治疗CAR19治疗后复发的R/R LBCL成人患者的效果。 ...